Hematologic Malignancies

Vascular Neurology

Questions discussed in this category

How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?

1 Answer available

What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?

New data suggests monoclonal gammopathies can be associated with thrombotic events. Is your practice changing to include monoclonal gammopathy evaluat...

1 Answer available

Papers discussed in this category

Blood Adv,

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.

Blood cancer journal, 2025 Apr 17

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.

Hematologic Malignancies

Vascular Neurology

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematologic Malignancies